Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy

Keyphrases

• Retrospective Analysis 100%
• Platinum-based Chemotherapy 100%
• Metastatic Urothelial Cancer 100%
• Satraplatin 100%
• Metastatic Cancer 62%
• Urothelial 62%
• Antitumor Activity 25%
• Platinum Agents 25%
• Disease Progression 12%
• Phase I Study 12%
• Transitional Cell Carcinoma 12%
• Cisplatin 12%
• Stable Disease 12%
• Objective Response 12%
• Carboplatin 12%
• Pharmacokinetics 12%
• Best Response 12%
• Adenocarcinoma 12%
• Renal Impairment 12%
• Heavily Pretreated 12%
• Resistant Cell Lines 12%
• Platinum Analogs 12%
• Refractory Solid Tumors 12%
• Cisplatin-resistant Cells 12%

Medicine and Dentistry

• Urothelial Cancer 100%
• Satraplatin 100%
• Chemotherapy 100%
• Metastatic Carcinoma 62%
• Antineoplastic Activity 25%
• Solid Malignant Neoplasm 12%
• Adenocarcinoma 12%
• Disease 12%
• Disease Exacerbation 12%
• Pharmacokinetics 12%
• Transitional Cell Carcinoma 12%
• Carboplatin 12%
• Cisplatin 12%
• Platinum Derivative 12%
• Cisplatin-Resistant Cell Line 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Chemotherapy 100%
• Satraplatin 100%
• Metastasis 62%
• Cisplatin 25%
• Antitumor Activity 25%
• Disease 12%
• Disease Exacerbation 12%
• Transitional Cell Carcinoma 12%
• Adenocarcinoma 12%
• Carboplatin 12%
• Solid Malignant Neoplasm 12%
• Platinum Derivative 12%
• Pharmacokinetics 12%